A panel of DNA methylation markers reveals extensive methylation in histologically benign prostate biopsy cores from cancer patients

被引：16

作者：

Brikun I. ^{[1
]}

Nusskern D. ^{[1
]}

Gillen D. ^{[2
]}

Lynn A. ^{[3
]}

Murtagh D. ^{[4
]}

Feczko J. ^{[5
]}

Nelson W.G. ^{[6
]}

Freije D. ^{[1
]}

机构：

[1] Euclid Diagnostics LLC, Crown Point, IN

[2] Department of Statistics, University of California Irvine, Irvine, CA

[3] Consultants in Laboratory Medicine, Toledo, OH

[4] Promedica Genitourinary Surgeons, Toledo, OH

[5] Pathology Consultants, Michigan City, IN

[6] Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD

来源：

Biomarker Research | / 2卷 / 1期

基金：

美国国家卫生研究院;

关键词：

Atypical small acinar proliferation; DNA methylation; Early cancer diagnostics; High grade prostatic intraepithelial lesions; Prostate cancer; Repeat biopsies;

D O I：

10.1186/s40364-014-0025-9

中图分类号：

学科分类号：

摘要：

Background: Men with a negative first prostate biopsy will undergo one or more additional biopsies if they remain at high suspicion of prostate cancer. To date, there are no diagnostic tests capable of identifying patients at risk for a positive diagnosis with the predictive power needed to eliminate unnecessary repeat biopsies. Efforts to develop clinical tests using the epigenetic signature of cores recovered from first biopsies have been limited to a few markers and lack the sensitivity and specificity needed for widespread clinical adoption.Methods: We developed methylation-specific quantitative polymerase chain reaction assays for a panel of 24 markers that are preferentially methylated in prostate cancer. We modified the bisulfite conversion conditions to allow the integration of the methylation information from multiple markers. We determined the methylation status of the 24 markers in 213 prostate biopsy cores from 104 patients, 37 prostate cancer patients and 67 controls. We performed logistic regression on combinations of markers as well as the entire panel of 24 markers to identify the best candidates for a diagnostic test.Results: The marker panel differentiated between cancer cores and benign cores from non-cancer patients with 100% sensitivity and 97% specificity. Furthermore, the panel detected significant methylation in benign cores from prostate cancer patients that was not present in controls. Using methylation of 5 out of 24 to define a cancer case, the analysis of a single benign biopsy core identified 62% of prostate cancer patients undergoing repeat biopsies. ROC curve analysis showed that markers commonly methylated in benign cores from cancer patients are the best candidates for a diagnostic test. The results suggest that 5 to 10 markers will be needed to achieve optimal predictive power.Conclusions: This study shows that epigenetic field effects differ significantly between cancer patients and controls. Their detection in benign biopsy cores can form the basis of diagnostic tests to identify patients in need of repeat biopsies, reducing the cost of continued PCA screening by up to 40%. They could also be used to identify prostate cancer patients with low grade disease who are likely candidates for active surveillance or focal therapy. © 2014 Brikun et al.

引用

共 57 条

[1]

Carter H.B., Albertson P.C., Barry M.J., Etzioni R., Freedland S.J., Green K.L., Holmberg L., Kantoff P., Konety B.R., Murad M.H., Penson D.F., Zietman A.L., Early detection of prostate cancer: AUA guideline, J Urol, 190, pp. 419-426, (2013)

[2]

Carter H.B., American Urological Association (AUA) guideline on prostate cancer detection: process and rationale, BJU Int, 112, pp. 543-547, (2013)

[3]

Rove K.O., Crawford E.D., Randomized controlled screening trials for prostate cancer using prostate-specific antigen: a tale of contrasts, Worl J Urol, 30, pp. 137-142, (2012)

[4]

Thompson I.M., Pauler D.K., Goodman P.J., Tangen C.M., Lucia M.S., Parnes H.L., Minasian L.M., Ford L.G., Lippman S.M., Crawford E.D., Crowley J.J., Coltman Jr C.A., Prevalence of prostate cancer among men with a prostate-specific antigen level <4.0 ng per milliliter, NEJM, 350, pp. 2239-2246, (2004)

[5]

Thompson I.M., Ankerst D.P., Chi C., Lucia M.S., Goodman P.J., Crowley J.J., Parnes H.L., Coltman C.A., Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower, JAMA, 294, pp. 66-70, (2005)

[6]

Roddam A.W., Duffy M.J., Ward A.M., Patnick J., Price C.P., Rimmer J., Sturgeon C., White P., Allen N.E., Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis, Eur Urol, 48, pp. 386-399, (2005)

[7]

Crawford E.D., Moul J.W., Rove K.O., Pettaway C.A., Lamerato L.E., Hughes A., Prostate-specific antigen 1.5-4.0 ng/ml: a diagnostic challenge and danger zone, BJU Int, 108, pp. 1743-1749, (2011)

[8]

Schroder F.H., Roobol M.J., Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer, Curr Opin Urol, 19, pp. 227-231, (2009)

[9]

Bokhorst L.P., Zhu X., Bul M., Bangma C.H., Schroder F.H., Roobol M.J., Positive predictive value of prostate biopsy by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial, BJU Int, 110, pp. 1654-1660, (2012)

[10]

Laurila M., van der Kwast T., Bubendorf L., di Lollo S., Pihl C.G., Ciatto S., Hugosson J., Maattanen L., Roobol M.J., Kujala P.M., Detection rates of cancer, high grade PIN and atypical lesions suspicious for cancer in the European randomized study of screening for prostate cancer, Eur J Cancer, 46, pp. 3068-3072, (2010)

← 1 2 3 4 5 6 →